Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 761 of 5804
-
Carbon ion beam takes aim at tough pancreatic tumors
Disease control CompletedIrradiation of non-operable pancreatic cancer with carbon ions (C12). This therapy is expected to be more effective than the current Gold Standard of photon irradiation applied in the case of non-operable pancreatic cancer.
Phase: NA • Sponsor: University Hospital Heidelberg • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Immune cell therapy shows promise for tough cancers
Disease control OngoingThis is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic cancer associated with one of the following can…
Phase: PHASE2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Experimental CAR t cell cocktail takes on recurrent glioblastoma
Disease control OngoingThis phase I trial studies the side effects and how well IL13Ralpha2-CAR T cells work when given alone or together with nivolumab and ipilimumab in treating patients with glioblastoma that has come back (recurrent) or does not respond to treatment (refractory). Biological therapi…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Can a cancer drug stop liver tumors from returning after ablation?
Disease control Recruiting nowFor early-stage hepatocellular carcinoma, i.e. Barcelona Clinical Liver Cancer Stage 0, ablation is the standard treatment with a comparable prognosis and less risk of ablation compared with liver resection. However, ablation is demanding on the surgeon and patients often face ea…
Phase: NA • Sponsor: Chen Xiaoping • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Can a Personality-Targeted program keep teens off drugs?
Prevention OngoingDespite having made some strides with respect to reducing adolescent drinking rates, illicit substance use and substance use disorders (SUDs) remain significantly above national targets for health promotion and disease prevention in Canada and the United States. Now, more than ev…
Phase: NA • Sponsor: St. Justine's Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:24 UTC
-
Gene-Guided drug cocktail shows promise for Tough-to-Treat gynaecological cancers
Disease control OngoingATARI trial tests the ATR inhibitor drug ceralasertib (AZD6738) alone and in combination with either a PARP inhibitor drug called olaparib, or an anti-PD-L1 immunotherapy called durvalumab (MEDI4736) in patients with relapsed gynaecological cancers to assess the response in group…
Phase: PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New vaccine aims to shield transplant patients from deadly virus
⭐️ VACCINE ⭐️ OngoingThis phase II trial studies how well Triplex vaccine works in preventing cytomegalovirus (CMV) infection in patients undergoing a hematopoietic stem cell transplantation. CMV is a virus that may be carried for life and does not cause illness in most healthy individuals. However, …
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:57 UTC
-
Could donor stem cells help lungs heal in ARDS?
Disease control CompletedThis is a Phase 2b, randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress Syndrome (ARDS). …
Phase: PHASE2 • Sponsor: Michael A. Matthay • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill shows promise for treating spinal arthritis in large trial
Disease control CompletedThis protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently. The main objectives of this protocol are: * To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adul…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for nigerian women with aggressive breast cancer: targeted therapy trial underway
Disease control OngoingThis is a one stage phase II study with a single arm design. It will be conducted in HER-2 positive breast cancer patients in Nigeria who are chemotherapy/hormonal treatment naive.
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can an inhaled protein save lungs in Alpha-1? new trial aims to find out
Disease control Recruiting nowThe goal of this clinical trial is to learn if AAT for inhalation, at a dose of 80 mg/day can slow the progression of lung disease in people who have lung disease caused by severe genetic deficiency in Alpha 1 Antitrypsin (AATD). The main question it aims to answer is: • Can da…
Phase: PHASE3 • Sponsor: Kamada, Ltd. • Aim: Disease control
Last updated Jun 26, 2026 13:26 UTC
-
New drug combo aims to tame myeloma in older patients without harsh chemo
Disease control OngoingThis is a Phase II study of daratumumab based therapies for older adults with multiple myeloma.
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for Tough-to-Treat leukemia: experimental drug DFP-10917 tested in Late-Stage trial
Disease control TerminatedPhase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day res…
Phase: PHASE3 • Sponsor: Delta-Fly Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New CT scanner aims to replace invasive heart tests for High-Risk patients
Diagnosis CompletedCardiac catheterization with invasive coronary angiography is the gold standard for determining the presence or absence of significant coronary heart disease (CHD). However, cardiac catheterization is costly and, as an invasive procedure, it is associated with some risk of advers…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Could two weeks of radiation be enough for breast cancer?
Disease control OngoingPatients with Stage 0 ductal carcinoma in situ (Tis (DCIS), Stage T1-T2, lymph node negative(N0) breast cancers will be randomized to receive whole breast radiotherapy with a concomitant boost to the tumor bed over 15 fractions (Arm 1, standard) versus 10 fractions (Arm 2, experi…
Phase: PHASE3 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New stem cell therapy aims to tame transplant complications
Disease control OngoingThis study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified he…
Phase: PHASE1 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Second-Chance CAR-T: could Off-Spec cells still fight cancer?
Disease control Recruiting nowThis study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved label by Japan Health Authority in Part 2. Only fo…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for aggressive breast cancer: two chemo cocktails face off in clinical trial
Disease control Recruiting nowThis is a multi-center , open-lable clinical trial. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have \<1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2. TNBC is diagnosed in 15-20% o…
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:49 UTC
-
New trial tests which chemo combo best shrinks tough breast tumors
Disease control Recruiting nowThis is a multicenter, open, randomized, comparison study. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have \<1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2. Neoadjuvant therapy i…
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:12 UTC
-
Brain cancer trial: one big dose or several small doses of radiation?
Disease control OngoingThis phase III trial studies how well single fraction stereotactic radiosurgery works compared with fractionated stereotactic radiosurgery in treating patients with cancer that has spread to the brain from other parts of the body and has been removed by surgery. Single fraction s…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC